Compare American Airlines Group Inc (AAL) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs AstraZeneca plc — how do they compare? American Airlines Group Inc trades at $15.05 (market cap $10.55B), while AstraZeneca plc trades at $157.71 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 23.5× American Airlines Group Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.
| AAL | AZN | |
|---|---|---|
Market Cap | $10.55B | $248.14B |
Sector | Industrials | Health |
52-Week High | $18.15 | $209.48 |
52-Week Low | $10.18 | $147.06 |
Enterprise Value | $38.51B | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.00, down 5.9% in the last 24 hours, with technical indicators signaling a bearish trend near support at $14. The company reported mixed earnings, beating estimates in Q1 and Q2 2026 but missing in Q4 2025, with revenue growth to $54.63 billion in 2025. However, net income margin remains negative at -0.56%, and high debt levels persist despite a declining trend.
AAL's outlook is cautious; while analyst consensus is a buy with a $19.63 price target, risks include volatile fuel costs, leverage, and thin profitability. The stock offers potential upside if premium revenue growth sustains, but investors face headwinds from operational margins and economic sensitivity.
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
